Navigation Links
Schering-Plough Announces Phase III Data for Sustained Follicle Stimulant
Date:7/8/2008

onadotropin (hCG). The primary endpoint was ongoing pregnancy rate assessed at 10 weeks or more after embryo transfer. The number of oocytes retrieved was the co-primary endpoint. The incidence of ovarian hyperstimulation syndrome (OHSS) was similar between both groups, 7.0 percent in the corifollitropin alfa group (1.9 percent severe) and 6.3 percent in the follitropin beta group (1.3 percent severe).

About corifollitropin alfa

Corifollitropin alfa is being developed as a potential treatment in Controlled Ovarian Stimulation (COS) for the development of multiple follicles and pregnancy in women participating in an Assisted Reproductive Technology (ART) program. The corifollitropin alfa regimen is being developed in a GnRH antagonist protocol.

About Schering-Plough

Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to Earn Trust, Every Day with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is http://www.schering-plough.com.

SCHERING-PLOUGH DISCLOSURE NOTICE: The information in this press release includes certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the plans for, the potential of and the potential market for corifollitropin alfa. Forward-looking statements relate to expectations or forecasts of future events. Schering-Plough does not assume the obligation to update any forward-looking statement. Many factor
'/>"/>

SOURCE Schering-Plough Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
2. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
3. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Hepatitis C Data Presentations at Digestive Disease Week (DDW) Annual Meeting
4. Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
5. Schering-Plough Announces Imperfect Contraceptive Use Impacts Womens Emotional Well-Being
6. Schering-Plough Initiates Phase II Study With Vicriviroc in Treatment-Naive HIV-Infected Patients
7. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
8. Schering-Plough Reports Top-Line Results of the IDEAL Study
9. Schering-Plough Announces Asenapine NDA Accepted for Filing by the U.S. FDA
10. Schering-Plough Highlights PEGINTRON(TM) Clinical Data Presentations at the American Association for the Study of Liver Diseases (AASLD) 2007 Annual Meeting
11. Pharmacopeia Earns Milestone Payment From Schering-Plough on Initiation of Phase 1 Clinical Trials of Novel Therapeutic Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  Array BioPharma Inc. (Nasdaq:   ARRY) ... quarter and full year of fiscal 2014 ... those results on Tuesday, August 12, 2014.  ... Michael Carruthers , Chief Financial Officer will ... 2014Time:9:00 a.m. Eastern TimeToll-Free:(800) 708-4540Toll:(847) 619-6397Pass Code: ...
(Date:7/28/2014)... July 28, 2014  Syneron Medical Ltd. (NASDAQ: ... announced today that its new PicoWay® device has received ... and colors and pigmented lesions on any skin type. ... with 532nm and 1064nm wavelengths, which utilizes Syneron,s proprietary ... pulses which are trillionths of a second, known as ...
(Date:7/28/2014)...  ResMed (NYSE: RMD ), an innovator ... sleep-disordered breathing and other chronic respiratory conditions, has won ... against Taiwanese medical device manufacturer APEX Medical Corp. (APEX), ... 210 and 220 masks.  The judgment was entered by ... , is appealable, and applies throughout Germany.  ...
Breaking Medicine Technology:Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4ResMed Receives Permanent Injunction against APEX in Germany, Continues Enforcement of Patents in Europe 2
... WASHINGTON, Sept. 29, 2011 As small businesses struggle ... indicates concern that forthcoming Essential Health Benefits regulations ... drug companies to raise prescription drug costs, the ... benefit managers (PBMs) administer drug benefits for thousands of ...
... Atrium Medical Corporation today announced the publication ... Vascular Surgery.  COBEST ( Covered Versus Balloon Expandable ... multi center, randomized, controlled clinical trial that has ... technology is superior to traditional bare metal stents ...
Cached Medicine Technology:Some Essential Benefits Rules Could Worry Small Businesses 2Atrium Announces the Publication of the COBEST Trial by the Journal of Vascular Surgery 2Atrium Announces the Publication of the COBEST Trial by the Journal of Vascular Surgery 3
(Date:7/28/2014)... (PRWEB) July 28, 2014 Shofner ... Operation Military June . Renowned LASIK and Cataract ... to provide significant funds and public awareness for ... retired military personnel and their families. “This was ... proudly give nearly $5,000 to a variety of ...
(Date:7/28/2014)... By Maureen Salamon ... (HealthDay News) -- Infants and children who are at ... should be vaccinated against the infection, according to updated ... States. And routine vaccinations for the potentially ... the American Academy of Pediatrics says. In its ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July 28, ... rhythm irregularities are more likely to get a pacemaker than ... the study of more than 16,000 people found that those ... get a pacemaker than those without the memory-robbing condition. ... with dementia are so much more likely to be treated ...
(Date:7/28/2014)... The Oakwood Foundation celebrated a major gift ... Associates, PC that will benefit each community we serve ... , The HBWS group is among the Foundation’s largest ... in donations. Through their latest gift, they will be ... Healthcare Classic for the next 6 years; provide state-of-the-art ...
(Date:7/28/2014)... Amy Norton HealthDay Reporter ... are commonly done to relieve sleep apnea in children, but ... weight gain -- especially if they,re already overweight. The ... factor for a range of health problems -- including, ironically, ... who need it. Instead, they said, doctors and parents ...
Breaking Medicine News(10 mins):Health News:Shofner Vision Center’s “Operation Military June” Provided Funds For Local Not-For-Profit Organizations Supporting Military And Their Families 2Health News:Shofner Vision Center’s “Operation Military June” Provided Funds For Local Not-For-Profit Organizations Supporting Military And Their Families 3Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 2Health News:Doctors Urge Meningitis Shots for Vulnerable Infants, Children 3Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 2Health News:Pacemakers Common for Those With Dementia and Irregular Heartbeats 3Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 2Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 3
... best biotechnology and best pharmaceutical agents honored,outstanding ... life-altering,diseases, NEW YORK, Sept. 25 - ... night recognized the innovations and,ingenuities of biotechnological ... of drugs that address pervasive illness and,diseases ...
... Connecting for Kids: Campaign 2008, a community of researchers, families ... of research. , ... (PRWEB) September ... for Kids: Campaign 2008], a community of researchers, families and ...
... Cell Therapeutics, Inc.,(CTI) (Nasdaq: CTICD and ... letter from The NASDAQ Stock Market confirming that it ... continued,listing on The NASDAQ Global Market under Marketplace Rule ... now closed., The Company continues its efforts to ...
... Electricity Rate Hike Adds to,Financial Woes, SPRINGFIELD, ... and Ameren customers converged on the,Illinois Commerce Commission ... Ameren,s $207 million rate hike. The ICC ignored ... customers, bills starting in,January., AARP is strongly ...
... Baker Offers Innovative New Bread to Promote Digestive ... ... As consumers are expecting,more from their daily bread, Mrs Baird,s, Texas, legendary ... in Texas. Mrs Baird,s today introduced Acti-Fiber,Wheat bread containing prebiotics fibers to ...
... DALLAS, Sept. 24 Presbyterian Hospital of,Dallas is one ... United States --,and the only Texas facility -- to ... conference, held this week,in Las Vegas, Nev., The ... on the latest advances in the treatment of peripheral ...
Cached Medicine News:Health News:Prix Galien USA Recognizes Biotech, Pharmaceutical Industries for Innovative Medical Treatments 2Health News:Prix Galien USA Recognizes Biotech, Pharmaceutical Industries for Innovative Medical Treatments 3Health News:New Site Launched for Families and Scientists to Discuss Stem Cell Research (US) 2Health News:Cell Therapeutics Regains Compliance with NASDAQ's Minimum Bid Price Requirement 2Health News:Cell Therapeutics Regains Compliance with NASDAQ's Minimum Bid Price Requirement 3Health News:Illinois Commerce Commission Delivers $207 Million Ameren Rate Hike 2Health News:Mrs Baird's Introduces Prebiotic Bread to Texas 2Health News:Dallas Cardiologists Explore 'Next Frontier' in Vascular-Disease Treatments 2
This camouflaging lens features the solid black stripes of the lightning fast African zebra, on a white iris background....
Medpor Sphere Inserter. The Inserter is provided as a value added item to Medpor Orbital Implants....
Reusable blunt cannula with luer hub. Cannula length is 32 mm....
... wall .90 mm (20 g) ... 6 mm in length. Cannula ... sclerotomy. 3201 has 16 cm ... tubing to allow injection of ...
Medicine Products: